60% of Covid-19 patients develop neurological symptoms

by Hospital Universitari de Bellvitge

60% of Covid-19 inpatients develop neurological symptoms and 12% of post-Covid patients have neurological sequelae, according to a panel discussion at the 2nd Covid-19 Multidisciplinary Congress moder...

Read more

Synendos Therapeutics Expands Series A to CHF 24 million with new investment. Ysios Capital joins other investors

by Ysios Capital

​Synendos Therapeutics (Synendos), a biopharmaceutical company focused on restoring the natural functioning of the endocannabinoid system to treat Central Nervous System (CNS) disorders, today annou...

Read more

La Vanguardia published a press release: 'The future of biotechnology: lower-cost treatments in a short period of time'

by Som Biotech

SOM Bio​tech has designed a computational Artificial Intelligence-based method to analyze molecular structures and select the best option after performing more than 2.5 million comparisons in each p...

Read more

Alta Life Sciences and CDTI invest €7.6M in Accure Therapeutics, a new company that will develop a portfolio of new medicines to address CNS diseases

by Alta Life Sciences / CDTI

Accure Therapeutics, a new pharma R&D player in the Central Nervous System (CNS) field, announces today its launch with a Series A round of funding totalling €7.6 million ($8.1M). The funding round ...

Read more

Minoryx Therapeutics doses first patient with leriglitazone in registration-enabling cALD NEXUS trial

by Minoryx Therapeutics

Pediatric Investigational Plan (PIP) for leriglitazone in X-ALD approved by EMA, allowing to file Marketing Authorization Application (MAA) in Europe based on NEXUS

Read more

Minoryx Therapeutics receives US FDA fast-track designation for leriglitazone in the treatment of X-ALD

by Minoryx Therapeutics

Leriglitazone (MIN-102), a novel, brain penetrant, orally bioavailable and selective PPARγ agonist, is currently in late-stage development for treatment of severe orphan CNS disorders, including X-AL...

Read more

A new experimental model to promote research on the neurological illness of Niemann-Pick type C

by Universitat de Barcelona

Niemann-Pick type C disease is a progressive serious neurological illness which causes accumulation of lipids in the central nervous system and several organs of the body, such as the liver and the sp...

Read more

A bee’s poison component can help improving drugs that treat brain diseases

by Universitat de Barcelona

A molecule, in particular a peptide designed out of bee’s poison, can become an important contribution to increase the efficiency of drugs treating the central nervous system. The research by Benjam...

Read more

VHIR creates the Spina Bifida Transversal Research Programme

by Vall d’Hebron

Spina bifida is the colloquial name by which neural tube defects are known. The most severe open form of neural tube defect compatible with life is the myelomeningocele, which implies affectation of t...

Read more

Neuron BioServices helps its clients to identify new drugs and ingredients able to face neuronal disorders and to improve learning and memory processes

by Neuron Bio

March 24th 2014 - Neuron Bioservices has developed a method to assay neurite outgrowth with differentiated neuronal cells to study neuroplasticity. The nervous system is an intricate network...

Read more

Sonia Blasco: La telerehabilitación permite que el paciente de una lesión neurológica reciba más tiempo de rehabilitación a un menor coste

by Universidad Católica de Valencia

La coordinadora clínica del Centro de Rehabilitación Neurológica Fivan participa en una jornada sobre nuevas tecnologías aplicadas a la práctica clínica en el Centro Autonómico de Referenci...

Read more
Subscribe to Directory
Write an Article

Recent News

Tuneable reverse photochromes in the sol...

A new technique allows the design of solid materia...

La Unidad de Chequeos de la Clínica sup...

El estudio realizado sobre una muestra significati...

Highlight

Interview with Dámaso Molero, general m...

by 3P Biopharmaceuticals

Dámaso Molero: “There are great opportunities in Latin America for ...

ORYZON reports results and corporate upd...

by Oryzon Genomics

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage...

Photos Stream